WO2017085630A1 - Composition et dispositif pour le traitement de tumeurs par ablation thermique - Google Patents

Composition et dispositif pour le traitement de tumeurs par ablation thermique Download PDF

Info

Publication number
WO2017085630A1
WO2017085630A1 PCT/IB2016/056887 IB2016056887W WO2017085630A1 WO 2017085630 A1 WO2017085630 A1 WO 2017085630A1 IB 2016056887 W IB2016056887 W IB 2016056887W WO 2017085630 A1 WO2017085630 A1 WO 2017085630A1
Authority
WO
WIPO (PCT)
Prior art keywords
poloxamer
composition
poloxamers
salt
needle
Prior art date
Application number
PCT/IB2016/056887
Other languages
English (en)
Inventor
Francesco Garbagnati
Original Assignee
H.S. Hospital Service S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H.S. Hospital Service S.P.A. filed Critical H.S. Hospital Service S.P.A.
Publication of WO2017085630A1 publication Critical patent/WO2017085630A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14—Probes or electrodes therefor
    • A61B18/1477—Needle-like probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
    • A61B18/1815—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053—Mechanical features of the instrument of device
    • A61B2018/00059—Material properties
    • A61B2018/00071—Electrical conductivity
    • A61B2018/00083—Electrical conductivity low, i.e. electrically insulating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053—Mechanical features of the instrument of device
    • A61B2018/00107—Coatings on the energy applicator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00053—Mechanical features of the instrument of device
    • A61B2018/00107—Coatings on the energy applicator
    • A61B2018/00136—Coatings on the energy applicator with polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00505—Urinary tract
    • A61B2018/00511—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00529—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00541—Lung or bronchi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
    • A61B2018/00577—Ablation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/44—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for cooling or heating the devices or media

Definitions

  • the present invention relates to devices and methods for the treatment of biological tissues, including the tumour ones, by means of thermal ablation (TA) induced by electromagnetic radiations, in the field of radio frequencies (RF) or microwaves (MW) or laser.
  • TA thermal ablation
  • RF radio frequencies
  • MW microwaves
  • the present invention relates to preparations and methods for implementing said preparations allowing to prolong the hydration conditions of tissues and/or to keep a low coupling impedance between active portion of the electrode and surrounding tissues even at high temperatures, in order to obtain thermal lesions with big volume and controlled shape.
  • One of the main problems of this type of procedure lies in the difficulty in destroying tumour masses having big sizes, in particular with a diameter larger than 3.0 cm, with one single insertion of the electrode.
  • the main reason is that the energy supplied through the electrode inserted into the tumour mass cannot be supplied indefinitely.
  • the dehydration of the tissue near the electrode takes place, which causes a quick increase in the electric impedance and consequently the impossibility of supplying further energy to the tissue.
  • Electrode-needles were described, allowing to obtain an increase in the volume of the thermolesion by injecting physiological saline solution during the thermoablation procedure.
  • such electrode-needles have not been inserted in the clinical practice as, due to the random spreading of the injected saline solution, the produced thermal lesions have an irregular shape and a not foreseeable volume.
  • compositions to be used with devices for thermoablation comprising salts and poloxamers.
  • the object of the present invention is then to provide a composition, a method for implementing such composition, a device and a method for TA solving the above- mentioned drawbacks, by maximising the volume of the thermal lesion for each gauge of used electrode and allowing to obtain thermal lesions with controllable and symmetric shape.
  • An important advantage provided by the present invention is the possibility of keeping the composition, set forth by the present invention, in the active electric field, in close contact with the electrode.
  • a second advantage provided by the present invention is the possibility of obtaining thermal lesions with sizes similar to those of the electrodes currently on the market with electrodes having much smaller gauge and then in a much less invasive way.
  • Another advantage is the possibility of obtaining thermal lesions with much larger diameter, the gauge being equal, with the electrodes currently on the market.
  • Another advantage of the present invention is the possibility of producing thermal lesions with reproducible sizes and shapes independently from the intrinsic features of the tissue to be treated (that is hydration, homogeneity, thermal and electrical conductivity, etc.).
  • An additional advantage of the present invention is the possibility of producing thermal lesions with relatively big diameter with electrode-needles having a very small gauge (21 -22G), so as to be then positioned in seats difficult to be reached.
  • the graph of Figure 2a represents state diagrams of some types of gel implemented to validate the present invention.
  • the electrical conductivity of some types of gel implemented to validate the present invention are compared to the electrical conductivities of the physiological solution and of the pig liver at different temperatures.
  • Figures 3a e 3b illustrate the quick action of becoming consistent of the gel injected in hot water.
  • Figures 4a-4e relate to an experiment for injecting 1 .0 cc of composition P27K100 in homogeneous porous medium saturated with conductive saline solution, slightly coloured in methylene blue to the purpose of displaying the state changes.
  • FIG. 5b illustrates the same results in terms of average values for group of experiments.
  • the present invention relates to a device for thermal ablation induced by electromagnetic energy comprising a composition received or receivable into said device, wherein the device is characterized in that such composition comprises one or more poloxamers (also defined poloxamers) and one or more salts soluble therein.
  • the device comprises one or more electrodes connected to a generator of radio frequency (3 kHz - 300 MHz), microwave (300 MHz - 300 GHz) or infrared (300 GHz - 430 THz) electromagnetic energy and a hollow element suitable for the injection of the composition in a tumour mass wherein said composition is received or can be received according to any one of the herein described embodiments.
  • the device comprises a carrying hollow cable extending in a main direction of longitudinal development and it is equipped with an electrically insulating coating on the whole outer surface thereof except for a distal portion, called exposed tip or active portion.
  • Said hollow element comprises at least an opening arranged in the active portion wherein the herein described composition is received or can be received. Examples of devices for thermal ablation suitable to be used with the compositions of the present invention are described in the patent application PCT/IB2013/053243 herein wholly incorporated by reference.
  • compositions comprising or constituted by water, poloxamers and one or more salts soluble in said preparations.
  • the poloxamers are constituted by a central hydrophobic chain of polyoxypropylene [polypropylene oxide)] flanked by two hydrophilic chains of polyoxyethylene [poly(ethylene oxide)].
  • poloxamer 407 (Pluronic® F-127) will be used.
  • Other poloxamers which could be used are poloxamer 237 (Pluronic F-87), poloxamer 288 (F-88), poloxamer 338 (F-108), poloxamer 188, poloxamer 127, poloxamer 237, poloxamer 235, poloxamer 335, poloxamer 405 or combinations thereof.
  • the salts of the composition could be selected among NaCI, Kl, or other salts, or other saline solutions, preferably the salt concentration will be selected so that the electric conductibility at 450 kHz of the final composition is at least 0.1 S/m. According to an embodiment the salt concentration will be at least 1 % by weight, preferably between 20% and 50% by weight.
  • the salt will be Kl in a concentration comprised between 1 % and 50% by weight, preferably between 30% and 50% by weight.
  • the concentration of the poloxamers, preferably of the poloxamer 407 is comprised between 10% and 40% by weight, preferably between 20% and 30% by weight.
  • the composition according to the present invention could be an aqueous solution constituted by copolymer and salts in the above mentioned concentrations; in particular the polymer will be poloxamer 407 and the salt Kl in amounts comprised between 30% and 50% or NaCI between 5% and 20% by weight.
  • the present invention also relates to the compositions according to any one of the herein described embodiments and the use thereof in a method for the treatment of a cancer, in particular for the use in a method for the treatment of ablation of cancers of the liver, of the lung, of the kidney and other parenchymal organs.
  • compositions of the present inventions could be in form of sterile or sterilisable liquid aqueous composition.
  • the present invention relates to a method for implementing a composition as herein described comprising a passage constituted by the mixing in water of poloxamer and one or more salts, so as to obtain the above mentioned concentrations.
  • the type of poloxamer and salts selected in the method could be any one of the above described ones, preferably they will be poloxamer 407 and Kl and/or NaCI.
  • the preparation method will include a step a. wherein a saline solution is prepared and a second step b. wherein poloxamer 407 is dissolved.
  • the preparation is cold-implemented; the cooling is obtained with a mixer at a temperature comprised between 4°C and 8°C for at least 36 hours.
  • the present invention relates to a method for the thermoablation treatment comprising the steps of:
  • thermoablation a device for the thermoablation, equipped with a hollow element, in tumour mass
  • tumour mass subjecting the tumour mass to energy at high frequencies so as to obtain the necrosis of the tissues.
  • thermolesion depend upon the spatial distribution of the temperature which, in each site, varies in time as a function of the heat produced in the same site by the electromagnetic field (thermal source) and by the diffusive/convective thermal flow produced by the temperature and pressure gradients.
  • the rate for heating the tissue in each site depends upon:
  • the local thermal source decreases by moving away from the needle with power comprised between 2 and 3 of the radial distance: then the value of the source by moving away from the needle decreases quickly (becoming negligible): for example at the distance of 10 needle beams it reduces (compared to the needle value) to 1 /100 with power 2, to 1/1000 with power 3. Beyond such distance the heating is controlled then mainly by the thermal diffusion, the characteristic time thereof depends upon the thermal diffusivity of the tissue and upon the field scale: for example by assuming the value 2 10 ⁇ 6 m 2 /s for the diffusivity and the centimetre as the needle scale, the characteristic time is in the order of 500 sec.
  • the heating speed is controlled by the source (heating is quick), whereas far from the needle the effect of the thermal transportation prevails (heating requires long periods of time).
  • the process duration is limited by the vaporisation of the liquids which, in turn, depends upon the time required to reach the boiling temperature near the needle: the power supply is interrupted as a result of the increase in impedance caused by the vaporisation of the existing liquids. If one works at constant power the deposited energy is proportional to time, then
  • the process result can be controlled by acting in two ways:
  • the specific heat of gel is higher than that of the liver, which prolongs the duration of the heating step.
  • the power deposited in the area occupied by the preparation is 0.9 W; in absence of preparation in the same volume a power of 15 W is deposited in the same volume. Then, by using the preparation, about 95% of the power supplied in proximity to the active electrode is "shifted" outside the area occupied by the gel. In conclusion, the injection transfers a portion of the power from the area near the electrode-needle to a farer area by reducing above all the maximum values of specific power in proximity to the needle ends.
  • Poloxamer 407 (Pluronic® F-127) is activated electrically by adding salt.
  • potassium iodide (Kl) was used. Potassium iodide (Kl) has a solubility in water about 4 times higher than sodium chloride (NaCI) but, the concentration being equal, it produces an increase in electrical conductivity of about half with respect to sodium chloride.
  • NaCI sodium chloride
  • the performed analyses showed that the preparations based upon this salt (of salting-in type) have a state behaviour more useful for the process at high temperatures.
  • the gel is prepared with the following mass proportions:
  • the preparation takes place in two steps: first of all the saline solution is prepared and afterwards poloxamer 407(for example Pluronic® F-127) is dissolved therein. This second step is performed in a bain-marie in water and ice at melting ice temperature, with a mixing of 30-60 minutes. The preparation is then made to rest at a temperature of about 4°C for about 36 hours before use.
  • poloxamer 407 for example Pluronic® F-127
  • the preparations were placed in transparent test tube and placed in water baths at prefixed temperatures in order to observe the status thereof at different temperatures:
  • the liquid is transparent
  • the gel is transparent or slightly opaque
  • the electrical conductivity of the preparations changes with the salt content.
  • the experience shows that at the temperature of 25°C the preparation P27K60 has a conductivity 7 times higher than that of the physiological solution whereas the conductivity of the preparation P27K100 is about 10 times higher than that of the physiological solution. Since at the reference temperature the electrical conductivity of the physiological solution is about 5.5 times higher than the typical one of the hepatic tissue it is deduced that the preparation P27K60 is about 40 times electrically more conductive than liver, whereas P27K100 is about 55 times more conductive than liver.
  • Figure 2b The bar representation of Figure 2b illustrates graphically the situation: the ordinate shows the conductivities in value related to that of the physiological solution.
  • the bar diagramme also shows the values at the temperature of 80°C to illustrate that the ratios between the conductivities are kept (or rather they are improved) by heating.
  • BASF provides a diagramme of viscosity of the polymeric solutions in function of the temperature parameterized with the percentage of poloxamer 407 (Pluronic®).
  • Such diagrammes highlight the fact that the copolymer viscosity is very high when this is at the gel status and much lower for the liquid state at low temperatures and of solubilized gel at high temperatures.
  • the viscosity further increases together with the percentage of poloxamer 407 (Pluronic®).
  • the preparations with poloxamer 407 (Pluronic®) appear to be always injectable very easily, both starting from the liquid state with gelification inside the receiving medium (at higher temperature), and starting from the gel status.
  • FIGS. 3a, 3b show the result of experiments of injection in water at constant temperature wherein the (almost instantaneous) change of state is taken which takes place when the preparation (coloured in methylene blue) is injected at the liquid state in water heated at 40°C. It is observed that the transformation at the gel status is practically instantaneous and the preparation lasts in this state for a relatively long period of time before hydrating and spreading in the surrounding water.
  • Figures 4a-4g instead, relate to an experiment for injecting 1 ml of preparation P27K100 in saturated homogeneous porous medium of conductive saline solution slightly coloured in methylene blue.
  • the first two images show the initial situation and the one taken at the end of the injection: it is observed that the preparation arranges around the injection site in substantially symmetrical way.
  • the subsequent images show the development during boiling.
  • the gel keeps unaltered during the power supply whereas the water included in the area limited by the magenta circle is boiling ( Figure 4c).
  • the boiling area even if it is not clear in the image, can be well identified in the video therefrom the figure is taken. Only at higher temperatures (about 1 10°C), reached after a slow heating, the change of state of the preparation (which progressively becomes opaque) takes place, followed by the power suspension (Figure 4d).
  • the preparation After cooling, the preparation recovers the original transparency and the volume thereof is slightly smaller than the original one (detail in Figure 4e).
  • the area occupied by gel at the beginning of the process and the resulting one after cooling are marked in black and white, respectively.
  • thermolesions A series of systematic thermolesions has been implemented, the conditions being equal and on similar tissue samples, in order to highlight the effect of different preparations in terms of:
  • the pig liver samples are constituted by 3 slices the central one thereof, which houses the active electrode and it is submitted to the preparation injection, is selected by paying particular attention to homogeneity;
  • tissue is pre-heated at 35°C - 37°C;
  • thermolesion which is obtained in absence of preparation: the process duration is in the order of ten seconds and the damaged volume reduces to a thickness in the order of the millimetre around the needle surface.
  • the use of the preparation allows to obtain lesions of the cm scale (1 .3-2.8 cm) in periods of time in the order of minute (0.7-2 min.).
  • thermolesion once deposited a "threshold energy", there is proportionality between duration (deposited energy) and volume of the thermolesion;
  • thermolesions generally are included in the tissue block wherein there is the needle and the bigger ones overflow in neighbouring blocks.
  • thermolesion volumes For each group the average values of the durations and of the corresponding thermolesion volumes are calculated represented in the graph of figure 5b.
  • the graph of figure 5b shows that:
  • the volume of the thermolesion grows proportionally with the duration, as it is to be expected by working at constant power
  • thermolesions obtained with P27K100 are always bigger than those obtained with P27K60 (represented in red), there are the biggest lesions with P27K100 and needle increased in section or length;
  • the increase in needle length is more effective than the increase in the section thereof (in harmony with the increase in needle exposed area).
  • the effect of the needle diameter is quantified by calculating and comparing the regression lines of the groups (1 +2+3+4) and (5+6)
  • thermolesion is obtained in less time with needle having a larger diameter.
  • the effect of the needle length is quantified by calculating and comparing the regression lines of the groups (1 +2+5+6) and (3+4)
  • thermolesion is obtained in less time with needle having longer length.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Plasma & Fusion (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des préparations, des dispositifs, des méthodes pour mettre en œuvre des préparations et des méthodes pour le traitement de tissus biologiques et de cancers par ablation thermique (TA) induite par énergie électromagnétique, par exemple dans le spectre des radiofréquences (RF), des micro-ondes (MW) ou de lumière laser. En particulier, l'invention concerne une préparation permettant de maintenir constantes les conditions d'hydratation des tissus et/ou à maintenir une faible impédance de couplage entre la partie active de l'électrode et les tissus environnants, même à des températures élevées, afin d'obtenir des lésions thermiques de grand volume et de forme régulée.
PCT/IB2016/056887 2015-11-20 2016-11-16 Composition et dispositif pour le traitement de tumeurs par ablation thermique WO2017085630A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102015000074840 2015-11-20
ITUB2015A005788A ITUB20155788A1 (it) 2015-11-20 2015-11-20 Composizioni e dispositivi per il trattamento di tumori mediante ablazione termica

Publications (1)

Publication Number Publication Date
WO2017085630A1 true WO2017085630A1 (fr) 2017-05-26

Family

ID=55538358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/056887 WO2017085630A1 (fr) 2015-11-20 2016-11-16 Composition et dispositif pour le traitement de tumeurs par ablation thermique

Country Status (2)

Country Link
IT (1) ITUB20155788A1 (fr)
WO (1) WO2017085630A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2579707A (en) * 2018-10-15 2020-07-01 Avent Inc Compositions, systems, kits, and methods for neural ablation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470703A1 (fr) * 1990-08-07 1992-02-12 MDV Technologies, Inc. Gels thermiquement réversibles et irréversibles
WO2000050004A2 (fr) * 1999-02-23 2000-08-31 Ioteck, Inc. Systeme d'administration d'anesthesiant pour une operation chirurgicale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
SE530015C2 (sv) * 2006-06-09 2008-02-12 Becare Orthopedic Thermal Care Högviskös komposition lämpad för muskelbehandling, vilken komposition innefattar polyoxyetylen-polyoxypropylen-blocksampolymer, samt dyna innefattande kompositionen
CN106037857A (zh) * 2008-02-29 2016-10-26 普拉罗美德公司 通过加热热敏聚合物进行的局部栓塞
US8628513B2 (en) * 2010-04-07 2014-01-14 Medtronic Vascular, Inc. Cell reservoirs created by polymer plugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470703A1 (fr) * 1990-08-07 1992-02-12 MDV Technologies, Inc. Gels thermiquement réversibles et irréversibles
WO2000050004A2 (fr) * 1999-02-23 2000-08-31 Ioteck, Inc. Systeme d'administration d'anesthesiant pour une operation chirurgicale

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2579707A (en) * 2018-10-15 2020-07-01 Avent Inc Compositions, systems, kits, and methods for neural ablation
US10799289B2 (en) 2018-10-15 2020-10-13 Avent, Inc. Compositions, systems, kits, and methods for neural ablation

Also Published As

Publication number Publication date
ITUB20155788A1 (it) 2017-05-20

Similar Documents

Publication Publication Date Title
US7393350B2 (en) Cryo-surgical apparatus and methods
US20090306654A1 (en) Device and method for the controlled thermal ablation of tumors by means of high-frequency electromagnetic energy
US6675050B2 (en) Computer program for microwave antenna
AU2015305374B2 (en) Systems and methods for spherical ablations
Yu et al. A comparison of microwave ablation and bipolar radiofrequency ablation both with an internally cooled probe: results in ex vivo and in vivo porcine livers
Yu et al. Comparison of percutaneous ablation technologies in the treatment of malignant liver tumors
Shi et al. Microwave ablation: results with double 915 MHz antennae in ex vivo bovine livers
WO2017085630A1 (fr) Composition et dispositif pour le traitement de tumeurs par ablation thermique
EP1804703B1 (fr) Appareil cryo-chirurgical
Kapp et al. Parameters predictive for complications of treatment with combined hyperthermia and radiation therapy
Burdío et al. Hepatic lesion ablation with bipolar saline-enhanced radiofrequency in the audible spectrum
Curley et al. Creation of large thermal lesions in liver using saline-enhanced RF ablation
WO2007113866A1 (fr) Dispositif et procédé d'ablation thermique de tumeurs au moyen d'énergie électromagnétique haute fréquence
Leveillee et al. Radiofrequency interstitial tissue ablation: wet electrode
KR20130092154A (ko) 고주파 수술용 전극 팁 및 이를 구비하는 고주파 수술용 전극
Lugnani et al. Cryoelectrolysis—electrolytic processes in a frozen physiological saline medium
CN103251452A (zh) 用于治疗肿瘤的双极消融电极
Ji et al. Preinjected fluids do not benefit microwave ablation as those in radiofrequency ablation
US20020010254A1 (en) Water-based coating composition having carbamate-melamine cross-linking, method of preparing the same, and a cured film therof
Shamekhi et al. Tumour shape-dependent microwave hyperthermia using a novel coaxial micro-cut slot antenna
RU2400171C2 (ru) Виртуальный электрод для высокочастотного разрушения биотканей и способ его изготовления и применения
Schaefer et al. Efficacy of direct electrical current therapy and laser-induced interstitial thermotherapy in local treatment of hepatic colorectal metastases: an experimental model in the rat
KR102590956B1 (ko) 겔 조성물 및 그의 제조 및 사용 방법
CN208910478U (zh) 一种分体式变径微波针
RU2318465C1 (ru) Способ микроволновой диатермокоагуляции биоткани и устройство для его осуществления

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16820334

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16820334

Country of ref document: EP

Kind code of ref document: A1